The positive preliminary data from the Phase 1 trial of XTX101 indicates that the potential cancer treatment is showing promising safety and tolerability profiles. This news is directly related to Xilio Therapeutics and its stock, as it demonstrates progress in the company's product pipeline. The positive results may lead to increased investor confidence and a potential short-term increase in the stock price.